The Sumaira Foundation
Stephanie H. possesses extensive experience in stakeholder engagement and advocacy within the pharmaceutical and healthcare sectors. Currently serving in a stakeholder engagement role at Johnson & Johnson Innovative Medicine since April 2021, Stephanie also holds a position as Director on The Sumaira Foundation's Board of Directors. Previously, Stephanie worked at Alexion Pharmaceuticals, Inc. from February 2020 to April 2021 as part of the Global Patient Advocacy team, where responsibilities included developing and executing advocacy strategies and enhancing relationships with patient groups. Prior to that, a career at Vertex Pharmaceuticals encompassed roles as Associate Director of Public Affairs, where efforts focused on Canadian market access for rare disease treatments, and as Associate Director of Stakeholder Relations. Earlier experience includes positions at Innomar Strategies, where Stephanie built patient services frameworks and managed specialty services, alongside roles at Bloor West Pharmacy.
This person is not in any teams
This person is not in any offices
The Sumaira Foundation
1 followers
The Sumaira Foundation is a 501(c)(3) organization dedicated to generating global awareness of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD), creating communities of support for patients and their caregivers, funding research and patient advocacy. NMOSD is a rare autoimmune disease that affects 10 out of 1 million patients and is oftentimes misdiagnosed as Multiple Sclerosis. The cause is unknown and there is no cure. Our founding philosophy is that heightened awareness will ultimately lead us towards finding a cure. To learn more about NMO and the organization, please visit www.sumairafoundation.org